Actelion Planning Tracleer Morbidity/Mortality IPF Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Actelion is planning a Phase III morbidity/mortality study of its pulmonary arterial hypertension therapy Tracleer (bosentan) for patients with idiopathic pulmonary fibrosis (IPF)